Cent AI Scans Aim to Detect Disease Before Symptoms Appear
The Bengaluru-based healthtech startup combines medical imaging, laboratory tests and doctor-reviewed AI analysis, backed by a new $15 million funding round.
Information checked on October 28, 2026
Cent AI scans are part of an effort to identify disease risks before people develop noticeable symptoms. The Bengaluru-based preventive healthcare startup combines full-body imaging, blood and urine tests, artificial intelligence and specialist review within a connected screening service.
The company’s ambition is to identify certain health problems potentially years before they would otherwise become apparent. It is also building a system for tracking changes over time, rather than relying only on a single examination.
On October 27, Cent announced $15 million in Series A funding, comprising equity and debt, co-led by Blume Ventures and existing investor South Park Commons.
The investment will support research and development and the expansion of its AI, engineering and clinical teams.
The Founders Behind Cent
Founded in 2025, Cent brings together entrepreneurs with experience in healthcare technology, consumer businesses and product development.
Its founders are Shashank ND, founder of Practo and OneFlow Holdings; Anshul Khandelwal, former chief marketing officer at Ola Electric; and Arpit Garg, former product head at Lenskart.
Cent identifies Shashank as its founder and board chair, Khandelwal as co-founder and chief business officer, and Garg as co-founder and chief AI and research officer.
Their business proposition centres on making preventive assessment a coordinated service, with imaging, laboratory analysis, reporting and medical consultations connected through one platform.
How Cent AI Scans Work
Cent’s approach combines several established medical tests. AI helps organise and analyse the resulting information, while medical professionals review the findings.
Its flagship offering, Cent Check, includes the following components:
| Component | Role in the assessment |
|---|---|
| MRI from head to pelvis | Examines organs and tissues for structural abnormalities |
| CT calcium scoring and lung imaging | Adds information about coronary calcium and lung health |
| DEXA scan | Measures bone density and body composition |
| ECG and echocardiography | Provide additional assessments of the heart |
| More than 100 blood and urine biomarkers | Assess metabolic health, organ function and other indicators |
The company says imaging takes approximately two hours at the centre. Blood and urine samples are collected separately at home.
The results then undergo AI-assisted synthesis and medical review. According to Cent’s current service information, the specialist-reviewed report is generally available within a week, followed by a consultation to explain the findings.
An optional genetics module adds an assessment of inherited risk factors.
Four Main Areas of Disease Risk
Cent organises its screening around a proprietary framework called CCNM, covering cancer, cardiovascular disease, neurological conditions and metabolic disorders.
The company says the protocol is designed to screen for more than 300 conditions.
That figure describes the scope of its screening programme. It should not be interpreted as a guarantee that every listed condition will be identified in every person.
Different tests contribute different information. Imaging can reveal structural changes, while laboratory markers can indicate changes in metabolism or organ function. Bringing these results together may help clinicians decide which findings need further investigation.
A screening abnormality, however, is not always a confirmed diagnosis. Some findings require additional imaging, laboratory tests or specialist assessment.
AI Supports Analysis and Medical Reporting
Cent describes AI as supporting image analysis, combining information from different tests and generating organ-level assessments.
Its technology is intended to help clinicians work through a large volume of information and present results in a more organised form. The company says specialists validate AI outputs.
Cent has also acquired Medsee, an AI-powered radiology reporting platform founded by Chitra Singh.
Medsee drafts structured reports and highlights findings for qualified radiologists to review. Cent expects the acquisition to improve reporting speed and consistency as its screening volumes increase.
The clinical decisions remain dependent on medical review, including the significance of an abnormality and whether further investigation is appropriate.
A Service That Continues After the Initial Scan
Cent Check includes follow-up across a year.
The company’s current programme provides a six-month checkpoint with repeat blood and urine testing and DEXA assessment. ECG and echocardiography may be repeated when recommended following the initial evaluation.
Members also receive access to up to four consultations concerning their screening findings, alongside reports and health information through the Cent app.
This structure allows the company to compare selected measurements over time. A change between assessments may provide information that a single result cannot.
Cent states that these consultations relate to its screening reports. They do not replace ordinary clinical care for new illnesses or symptoms.
What Cent’s Early Findings Show
In its funding announcement, Cent reported reaching approximately 10,000 members. It said one in four people who arrived feeling well had a finding considered worth acting on.
These are company-reported observations from people using its service. They should not be treated as estimates of disease prevalence across India.
They also do not establish how many findings would have caused future illness, how many required further testing that proved unnecessary, or whether the programme improves long-term survival.
Those questions matter when assessing the value of any broad screening service.
The Evidence Limits Around Full-Body Screening
Finding a condition earlier can be useful when the test is appropriate and an effective intervention is available. Broad screening of people without symptoms requires evidence that its benefits outweigh its potential harms.
The American College of Radiology has stated that evidence is insufficient to recommend total-body MRI screening for people without symptoms, relevant risk factors or a concerning family history.
Its concerns include uncertain findings that lead to additional procedures and expense without necessarily improving health.
MRI does not use ionising radiation. CT and DEXA do use X-rays, so the combined screening package should not be described as entirely radiation-free.
The suitability of screening depends on the individual’s history and risk profile. A reassuring screening report also cannot rule out every illness or replace assessment of new symptoms.
What Comes Next for Cent
Cent’s founders have outlined plans to develop dedicated hardware, improve the integration of imaging and biological data, and build health reference information relevant to Indian populations.
The company has set a target of 10 million scans by 2035.
Reaching that scale will require more than additional scanning capacity. Consistent interpretation, appropriate referrals, accessible pricing and dependable follow-up will be central to the service.
For Cent, the next important evidence will concern what happens after a finding: whether it leads to an appropriate diagnosis, useful treatment and better outcomes for the people being screened.
For more insights navigate: PressPire | Stories That Shape the Future
Read previous article here : cyclone-arnab-andhra-landfall-october-28-2026/
Follow PressPire on Facebook | Instagram | LinkedIn | YouTube
PressPire | Stories That Shape the Future
